Ask Warren

Korea Arlico Pharm

260660 · KOSDAQ · ₩260660 · 알리코제약

₩1,864▼ ₩16 (0.85%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩47B₩48B₩48B₩52B₩50B₩50B₩52B₩49B
Cost of sales₩24B₩22B₩24B₩26B₩24B₩24B₩26B₩22B
Gross profit₩22B₩26B₩25B₩26B₩27B₩27B₩26B₩26B
Operating income−₩4.6B−₩1.8B−₩1.7B₩4M₩1.7B₩1B−₩642M₩1.3B
Net income−₩694M−₩621M−₩983M−₩554M₩533M₩399M−₩1.7B₩1.1B
Net income to shareholders−₩694M−₩621M−₩983M−₩554M₩533M₩399M−₩1.7B₩1.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩171B₩171B₩172B₩174B₩174B₩172B₩172B₩164B
Current assets₩82B₩82B₩83B₩87B₩89B₩85B₩85B₩76B
Cash and equivalents₩18B₩18B₩19B₩16B₩15B₩13B₩15B₩13B
Total liabilities₩95B₩94B₩94B₩95B₩94B₩93B₩93B₩81B
Current liabilities₩79B₩75B₩74B₩76B₩75B₩74B₩75B₩65B
Borrowings₩11B₩12B₩16B₩16B₩17B₩17B₩16B₩16B
Total equity₩76B₩77B₩78B₩79B₩80B₩79B₩80B₩84B
Shareholders' equity₩76B₩77B₩78B₩79B₩80B₩79B₩80B₩84B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩4.5B₩2.9B₩8.2B₩2.1B₩1.5B−₩1.8B₩39M−₩531M
Capital spending₩56M₩807M₩943M₩410M₩289M₩1.5B₩106M₩624M
Free cash flow₩4.5B₩2.1B₩7.3B₩1.7B₩1.2B−₩3.3B−₩67M−₩1.2B
Dividends paid₩81M₩79M₩80M₩80M₩93M₩99M₩115M₩70M

Consolidated where available. Amounts in won.

Also known as: Korea Arlico Pharm / 알리코제약 / 260660 / KRX:260660

Source: KRX statistical information